{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T23:34:42Z","timestamp":1775345682711,"version":"3.50.1"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.7623","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T18:18:26Z","timestamp":1490984306000},"page":"841-846","source":"Crossref","is-referenced-by-count":7,"title":["The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient"],"prefix":"10.2169","volume":"56","author":[{"given":"Kensei","family":"Taguchi","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Moriyama Clinic of Internal Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goh","family":"Kodama","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Fukami","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Desnick R. The Metabolic and Molecular Bases of Inherited Disease Vol. 3. 8th Ed. McGraw Hill, New York, 2001: 3733-3774."},{"key":"2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 281: 249-254, 1999.","journal-title":"JAMA The Journal of the American Medical Association","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mechtler TP, Stary S, Metz TF, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 28; 379: 335-341, 2012.","DOI":"10.1016\/S0140-6736(11)61266-X"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79: 31-40, 2006.","DOI":"10.1086\/504601"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-2749, 2001.","DOI":"10.1001\/jama.285.21.2743"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Feriozzi S, Torras J, Cybulla M, et al. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol 7: 60-69, 2012.","DOI":"10.2215\/CJN.03130411"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Pisani A, Spinelli L, Sabbatini M, et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 46: 120-127, 2005.","DOI":"10.1053\/j.ajkd.2005.03.016"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. de Fost M, Out TA, de Wilde FA, et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 87: 439-449, 2008.","DOI":"10.1007\/s00277-008-0441-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis 32: 214-217, 2004.","DOI":"10.1016\/j.bcmd.2003.10.007"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. Clonal immunoglobulin against lysolipids in the origin of myeloma. N Engl J Med 374: 555-561, 2016.","DOI":"10.1056\/NEJMoa1508808"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Pokuri VK, Xu B, Neppalli V, et al. Synchronous presentation of monoclonal gammopathy and Fabry nephropathy; diagnostic renal biopsy obviates initiation of myeloma therapy. Ann Hematol 94: 1067-1068, 2015.","DOI":"10.1007\/s00277-015-2307-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase \u03b2 therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547-1557, 2007.","DOI":"10.1681\/ASN.2006080816"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121: 749-757, 2003.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cohen G, Rudnicki M, Schmaldienst S, H\u00f6rl WH. Effect of dialysis on serum\/plasma levels of free immunoglobulin light chains in end-stage renal disease patients. Nephrol Dial Transplant 17: 879-883, 2002.","DOI":"10.1093\/ndt\/17.5.879"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 85: 255-259, 2005.","DOI":"10.1016\/j.ymgme.2005.04.009"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/7\/56_56.7623\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T10:00:39Z","timestamp":1498384839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/7\/56_56.7623\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.7623","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}